James W Welsh

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer
    James Welsh
    Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Med Dosim 38:442-7. 2013
  2. pmc Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 7:152. 2012
  3. pmc Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
  4. pmc Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2632-40. 2012
  5. pmc Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study
    James Welsh
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:1336-42. 2011
  6. pmc Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy
    James Welsh
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:91-6. 2011
  7. pmc Esophageal cancer dose escalation using a simultaneous integrated boost technique
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:468-74. 2012
  8. pmc Update: modern approaches to the treatment of localized esophageal cancer
    James Welsh
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 13:157-67. 2011
  9. pmc The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
  10. ncbi request reprint The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma
    Ashleigh M Francis
    Departments of Thoracic and Cardiovascular Surgery, GI Medical Oncology, Diagnostic Radiology, GI Medicine and Nutrition, Pathology, Radiation Therapy, and Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:500-7. 2013

Collaborators

Detail Information

Publications24

  1. pmc Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer
    James Welsh
    Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Med Dosim 38:442-7. 2013
    ....
  2. pmc Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 7:152. 2012
    ..However, factors that may predict toxicity or survival are largely unknown. We sought here to identify predictors of survival and pneumonitis after SABR for NSCLC in a relatively large single-institution series...
  3. pmc Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
    ..Additional end points were radiologic response and safety...
  4. pmc Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2632-40. 2012
    ..Little is known about the failure pattern based on modern-day radiation treatment volumes. We hypothesized that most local failures would be within the gross tumor volume (GTV), where the bulk of the tumor burden resides...
  5. pmc Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study
    James Welsh
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:1336-42. 2011
    ..In the present study, we compared the dosimetric parameters for photon IMRT with that for intensity-modulated proton therapy (IMPT) for unresectable, locally advanced, distal esophageal cancer...
  6. pmc Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy
    James Welsh
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:91-6. 2011
    ..We attempted here to identify dose-volume parameters that predict chest wall toxicity (pain and skin reactions) in patients receiving thoracic SBRT...
  7. pmc Esophageal cancer dose escalation using a simultaneous integrated boost technique
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:468-74. 2012
    ..We performed a planning study to evaluate if a simultaneous integrated boost (SIB) technique could selectively deliver a boost dose of radiation to the GTV in patients with esophageal cancer...
  8. pmc Update: modern approaches to the treatment of localized esophageal cancer
    James Welsh
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 13:157-67. 2011
    ....
  9. pmc The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
    ..We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy...
  10. ncbi request reprint The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma
    Ashleigh M Francis
    Departments of Thoracic and Cardiovascular Surgery, GI Medical Oncology, Diagnostic Radiology, GI Medicine and Nutrition, Pathology, Radiation Therapy, and Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:500-7. 2013
    ..Our aim was to validate the effect of histopathologic tumor viability (HTV) on extended survival outcomes and assess the prognostic ability of the current staging system in patients receiving preoperative chemoradiotherapy (CRT)...
  11. pmc Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 119:3402-10. 2013
    ..However, a significant proportion of patients with MPLC cannot undergo surgery. For this report, the authors explored the role of stereotactic ablative radiotherapy (SABR) for patients with MPLC...
  12. doi request reprint Metformin use and improved response to therapy in esophageal adenocarcinoma
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 52:1002-9. 2013
    ..We investigated the radiographic and pathologic response rate of esophageal adenocarcinoma treated with neoadjuvant chemoradiation in patients taking metformin...
  13. ncbi request reprint Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma
    Caitlin C Murphy
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Gastrointest Surg 17:1359-69. 2013
    ..We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy...
  14. ncbi request reprint Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer
    Arya Amini
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 21:306-14. 2014
    ..We analyzed patients who reached cCR after definitive chemoradiation for esophageal cancer to identify clinical predictors of local disease recurrence...
  15. doi request reprint Cardiac ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy
    Jaden D Evans
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States Texas Tech University Health Sciences Center School of Medicine, Lubbock, United States
    Radiother Oncol 109:82-8. 2013
    ..We reviewed patients treated with thoracic stereotactic body radiation therapy (SBRT) and established correlations between SBRT dose and observed changes in cardiac FDG-PET uptake...
  16. pmc Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:1060-70. 2012
    ....
  17. pmc Progress in the management of limited-stage small cell lung cancer
    Arya Amini
    Department, of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas University of California at Irvine School of Medicine, Irvine, California
    Cancer 120:790-8. 2014
    ..Future improvements in outcomes will require clarifying the molecular basis for this disease...
  18. pmc Aortic dose constraints when reirradiating thoracic tumors
    Jaden D Evans
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Radiother Oncol 106:327-32. 2013
    ..Improved radiation delivery and planning has allowed, in some instances, for the retreatment of thoracic tumors. We investigated the dose limits of the aorta wherein grade 5 aortic toxicity was observed after reirradiation of lung tumors...
  19. pmc Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy
    Vikas Bhardwaj
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 119:1768-75. 2013
    ..This article summarizes key findings regarding crosstalk between radiotherapy and c-Met and discusses studies performed to date in which c-Met inhibition was used as a strategy to increase cellular radiosensitivity...
  20. doi request reprint Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy
    Akihiro Suzuki
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:108-13. 2012
    ..We used a number of clinical pre- and post-treatment parameters to establish two nomograms: for overall survival (OS) and relapse-free survival (RFS)...
  21. ncbi request reprint Lymphopenia association with gross tumor volume and lung v5 and its effects on non-small cell lung cancer patient outcomes
    Chad Tang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Int J Radiat Oncol Biol Phys 89:1084-91. 2014
    ..Radiation therapy (RT) can both suppress and stimulate the immune system. We sought to investigate the mechanisms underlying radiation-induced lymphopenia and its associations with patient outcomes in non-small cell lung cancer (NSCLC)...
  22. ncbi request reprint Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies
    Lehendrick M Turner
    The University of Texas M D Anderson Cancer Center School of Health Professions, Medical Dosimetry Program, Houston, TX, USA
    Med Dosim 36:383-8. 2011
    ..The target's mean doses were significantly increased based on p-value analysis, while the normal tissue structures were not significantly changed...
  23. ncbi request reprint Rad51 protein expression and survival in patients with glioblastoma multiforme
    James W Welsh
    Department of Radiation Oncology, University of Arizona College of Medicine, Tucson, AZ, USA
    Int J Radiat Oncol Biol Phys 74:1251-5. 2009
    ..We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival...
  24. ncbi request reprint Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer
    Maria Angelica Cortez
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Mol Ther 22:1494-503. 2014
    ....